Clinical Trial Detail

NCT ID NCT03658772
Title Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Arrys Therapeutics
Indications

colorectal cancer

Therapies

Grapiprant + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST